Annexin Pharmaceuticals AB (ANNX) — Working Capital to Net Assets Ratio
Annexin Pharmaceuticals AB (ANNX) has a Working Capital to Net Assets ratio of 89.3% as of March 2026. Working capital of Skr12.87 Million (current assets of Skr18.43 Million minus current liabilities of Skr5.56 Million) is measured against net assets of Skr14.42 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See ANNX equity financing ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Annexin Pharmaceuticals AB Working Capital to Net Assets (2014–2025)
This chart shows how Annexin Pharmaceuticals AB's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of March 2026, the ratio stands at 89.3%, reflecting working capital of Skr12.87 Million against net assets of Skr14.42 Million SEK. Check Annexin Pharmaceuticals AB tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Annexin Pharmaceuticals AB (2014–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Annexin Pharmaceuticals AB from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market value of Annexin Pharmaceuticals AB.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 93.6% | Skr23.34 Million | Skr24.93 Million | Skr28.57 Million | Skr5.22 Million | ▲ +5.7 pp |
| 2024 | 87.9% | Skr12.06 Million | Skr13.71 Million | Skr17.38 Million | Skr5.32 Million | ▼ -2.2 pp |
| 2023 | 90.2% | Skr16.97 Million | Skr18.81 Million | Skr24.91 Million | Skr7.95 Million | ▲ +0.2 pp |
| 2022 | 90.0% | Skr27.12 Million | Skr30.15 Million | Skr33.65 Million | Skr6.53 Million | ▼ -5.6 pp |
| 2021 | 95.6% | Skr44.66 Million | Skr46.73 Million | Skr50.72 Million | Skr6.06 Million | ▲ +6.5 pp |
| 2020 | 89.0% | Skr18.38 Million | Skr20.64 Million | Skr22.90 Million | Skr4.52 Million | ▲ +9.6 pp |
| 2019 | 79.5% | Skr9.13 Million | Skr11.49 Million | Skr13.68 Million | Skr4.55 Million | ▼ -14.7 pp |
| 2018 | 94.2% | Skr37.53 Million | Skr39.85 Million | Skr43.49 Million | Skr5.96 Million | ▲ +3.2 pp |
| 2017 | 90.9% | Skr22.23 Million | Skr24.44 Million | Skr28.16 Million | Skr5.93 Million | ▼ -4.9 pp |
| 2016 | 95.8% | Skr14.93 Million | Skr15.57 Million | Skr22.08 Million | Skr7.16 Million | ▲ +687.8 pp |
| 2015 | -592.0% | Skr811.00K | Skr-137.00K | Skr1.69 Million | Skr883.00K | ▼ -656.6 pp |
| 2014 | 64.6% | Skr1.75 Million | Skr2.71 Million | Skr2.03 Million | Skr281.14K | — |